WARNINGS AND PRECAUTIONS1
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.
Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.
Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
(N = 513)
(N = 506)
|Injection-site reactions||492 (96%)||411 (81%)|
|Edema/swelling||448 (87%)||218 (43%)|
|Hematoma/bruising||368 (72%)||353 (70%)|
|Pain||356 (70%)||160 (32%)|
|Numbness||341 (66%)||29 (6%)|
|Erythema||136 (27%)||91 (18%)|
|Induration||120 (23%)||13 (3%)|
|Paresthesia||70 (14%)||20 (4%)|
|Nodule||68 (13%)||14 (3%)|
|Pruritus||64 (12%)||30 (6%)|
|Skin tightness||24 (5%)||6 (1%)|
|Site warmth||22 (4%)||8 (2%)|
|Nerve injuryb||20 (4%)||1 (< 1%)|
|Headache||41 (8%)||20 (4%)|
|Oropharyngeal pain||15 (3%)||7 (1%)|
|Hypertension||13 (3%)||7 (1%)|
|Nausea||12 (2%)||3 (1%)|
|Dysphagia||10 (2%)||1 (< 1%)|
aAdverse reactions that occurred in ≥ 2% of KYBELLA® treated subjects and at greater incidence than placebo.
bMarginal mandibular nerve paresis.
See results of patients treated with KYBELLA® injection. Individual results may vary.VIEW
For adults with moderate to severe submental fat (double chin):
KYBELLA® permanently destroys fat cells in the treatment area under the chin for an improved profile.
*Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart.
Register to watch the Online Training Video to become a trained KYBELLA® injector.REGISTER
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.